The directors of the Irish arm of pharma giant Roche have stated that there is a need to reduce the lengthy timelines to ...

The lengthy timelines to reimburse medicines in Ireland must be reduced to improve standards of care and patient outcomes, ...

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

The brand came to develop products specifically designed for dermatologists and skin care professionals to treat patients ...

including any devices which may directly compete with Roche products. Extra financial resources from the acquisition will go toward recruitment, product improvement, and building more ...

We asked a dermatologist to weigh in on the best moisturizing hacks for every skin type during winter. She suggested products ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, but growth may accelerate after 2026. Read more here.

Late-stage trial data for Roche’s drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy.

Swiss pharma giant Roche today released full-year 2024 financials, showing that group sales grew 7% at constant exchange rates (3% in francs) to 60.5 billion francs ($66.9 billion).

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has become the first regulator to approve Roche's subcutaneous (SC) formulation of cancer immunotherapy Tecentriq, which aims to ...